Thyroid Eye Disease
Teprotumumab, a human monoclonal anti-IGF-1R blocking antibody, reduced proptosis in a series of patients with non-inflammatory thyroid eye disease (TED), according to a study.
Four patients with non-inflammatory TED were treated with a complete course (8 infusions) of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions every 3 weeks).
After treatment, there was a mean (SD) reduction…
featured stories
View Conference Coverage
Take a look at some of our conference coverage, visit our roundup section.
Videos
-
Nov 13, 2020
AAO: Management of Thyroid Eye Disease
-
Nov 13, 2020
Treatment Options for Thyroid Eye or Graves’…
-
Nov 13, 2020
TEPEZZA x Horizon Therapeutics
Conference Roundup
- Nov 23, 2020
TED Talks: AAO Virtual 2020 provides the latest on thyroid eye disease
During a series of lectures on thyroid eye disease (TED) during the recently-concluded AAO 2020 Virtual conference, Steven M. Couch, MD, presented a to-do list for patients with…
Journal Scan
- Dec 14, 2020
Use of automated imaging metrics in TED may provide rapid clinical information
The use of automated imaging metrics in thyroid eye disease has the potential to provide rapid clinical information that could identify visual impairments in earlier stages, potentially leading to better treatment options, according to a study.
In this study, 204 CT images of orbits in…
Trending Topics
- Nov 20, 2020
Webinar tackles patient, physician experience with TED
A new webinar, “Dealing with Thyroid Eye Disease: Patient and Physician Perspectives" provides insights into the patient and physician experience with thyroid eye disease (TED).
Hosted by the Graves’ Disease & Thyroid Foundation, the webinar covers topics such as the impact age has…
-
-
-
-
FDA Approves First Treatment for Thyroid Eye Disease
Mar 01, 2020